Sorrento Licenses COVID-19 Saliva Test

California-based Sorrento Therapeutics has secured the rights to a rapid SARS-CoV-2 saliva test developed at Columbia University that produces results within 30 minutes.

The point-of-care test, which will be named COVI-TRACE, requires no laboratory equipment and can identify the virus from a small saliva sample. The rapid test could be used to test air travelers before they board aircraft, the company said.

Sorrento said it will seek an Emergency Use Authorization from the FDA in the coming weeks.